---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-001077"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2026-01-02T23:59:59+00:00"
generated_at: "2026-05-16T11:51:13.423911+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics receives Nasdaq delisting notice for bid price non-compliance; plans hearing and reverse split vote

## Summary
- Nasdaq notified delisting on Dec 30, 2025, after 180-day cure period ended Dec 29 without compliance.
- Company plans to request a hearing before the Nasdaq Hearings Panel to stay delisting.
- Proxy filed Dec 29 seeking stockholder approval for reverse stock split (1-for-5 to 1-for-30).
- No assurance of extension or successful regaining of compliance with $1.00 bid price rule.

## SEC filing metadata
- accession: 0001193125-26-001077
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2026-01-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000119312526001077/0001193125-26-001077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000119312526001077/fblg-20251230.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-001077
- JSON: https://secwatch.observer/filing/0001193125-26-001077.json
- Plain text: https://secwatch.observer/filing/0001193125-26-001077.txt

## Key facts
- Listing & Compliance Notices
  FibroBiologics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: July 1, 2025, FibroBiologics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the bid price for the Company’s shares of common stock had closed below the minimum threshold of $1.00 per share, as required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”), for the previous 30 consecutive trading day period. In accordance with Listing Rule 5810(c)(3)(A), the Company was provided with a 180-calendar day period to regain compliance with t
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000119312526001077/0001193125-26-001077-index.htm
- Listing & Compliance Notices
  FibroBiologics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: December 30, 2025, the Company received a second notification indicating that the Staff planned to delist the Company’s securities due to the Company’s continued non-compliance with the Rule as of December 29, 2025, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing before the Panel, which request will stay any further suspension or delisting action by the Staff at least pending the outcome of the hearing and the expiration of any extension that may be granted to the Company by the Panel. The Company intend
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000119312526001077/0001193125-26-001077-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.